Navigation Links
KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody
Date:12/10/2013

unogenicity and clinical activity. The investigators also evaluated EphA3 expression on tumor, stromal and endothelial cells.

Nestor Molfino, M.D., MSc, KaloBios' Chief Medical Officer, commented, "KB004 targets EphA3, which is expressed in adults on hematologic malignancies and solid tumors, including tumor stem cells, but not on normal blood or bone marrow stem cells. The targeted nature of this antibody may represent a promising approach to selectively treat patients with hematologic malignancies. As we have not yet reached a maximum tolerated dose, we will continue to study higher doses of KB004 as part of this ongoing trial to determine an optimum high-end dose for the Phase 2 expansion portion of the study in patients with AML or myelodysplastic syndrome (MDS) which is expected to begin by the end of the year."

The poster presented at ASH can be viewed on the KaloBios website.

About KaloBios

KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer.

Currently, KaloBios has three drug development programs:

  • KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases, being developed for the treatment of severe asthma. Enrollment of 160 patients has been completed in a Phase 2 study in the United States, Europe and Australia.
  • KB001-A, an anti-PcrV mAb fragment, partnered exclusively with Sanofi Pasteur and is being developed for the pr
    '/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
2. Wyss Institute at Harvard University announces election of 2 faculty to Natl Academy of Inventors
3. Reproductive Health Matters announces publication of its latest themed issue: New development paradigm
4. Afterburn Fuel Review Announces the Launch of its New and Informative Website
5. VaxTrac Announces Continued Support for Expansion of Biometric-based Mobile Vaccine Registry Programs in Benin
6. AIBS announces winners of Faces of Biology photo competition
7. NERC announces the winner of its first photo and essay competition
8. Elsevier announces the launch of open access journal: Current Plant Biology
9. AVS Announces Its Major Award Winners of 2013
10. The Association for Molecular Pathology announces highlights of Phoenix meeting
11. EMBO announces the launch of EMBO Press
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 Fingerprint Cards has received ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... be used by smartphone manufacturers in Asia ... the communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
(Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... Netherlands,Thursday 25 April 2013: Probiotics could emerge as ... therapy after a new study announced at ... reduced development of the notoriously difficult-to-treat disease. ... preventing the development of HE in 160 cirrhotic ...
... Liver Congress 2013 include results from early in vitro ... (cccDNA), which may form the basis of a cure ... cccDNA is organized into mini-chromosomes within the nucleus of ... availability of efficient therapies against HBV, long-term persistence of ...
... 2013, a novel H7N9 influenza virus was identified in ... in humans, resulting in some deaths. A group of ... Reference Laboratory, State Key Laboratory of Veterinary Biotechnology, Harbin ... investigated the origins of this novel H7N9 influenza virus ...
Cached Biology News:Probiotics found to reduce hepatic encephalopathy 2Novel therapeutic approaches to cure chronic HBV infection 2Novel therapeutic approaches to cure chronic HBV infection 3Source identification of H7N9 influenza virus causing human infections 2Source identification of H7N9 influenza virus causing human infections 3
(Date:7/3/2015)... 3, 2015 ... osoitteessa  http://www.openinnovationinscience.at Wienissä pidettävään ... Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... tekemän, kansainvälisiä tutkijoita ja tiedemiehiä ... suurinta haastetta ovat kannustimien puute ...
(Date:7/3/2015)... ... July 03, 2015 , ... The global failure analysis market is expected to ... The bioscience market is expected to grow at the highest CAGR of 8.46%; its ... in the research labs and academic institutions for root cause analysis of failure. The ...
(Date:7/3/2015)... 2015 Forskere kan ... in Science", som finner sted i ... nett, på  http://www.openinnovationinscience.at , og søknadsperioden varer ... De to største utfordringene innen helsevitenskapen er ... forskningsspørsmål og kompleksiteten av nåværende forskningsresultater, i ...
(Date:7/3/2015)... July 3, 2015 ... september 2015 på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet ... finder sted i Wien ... af internationale forskere og videnskabsmænd foretaget af ... største udfordringer for sundhedsvidenskaben manglen på incitamenter ...
Breaking Biology Technology:Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3
... Reportlinker.com announces that a new market research report ... Biomarkers - Technologies,markets and companies ... follows the broad definition of a biomarker as ... evaluated as an indicator of normal biological or ...
... 2011 Reportlinker.com announces that a new ... catalogue: The 2011 Blood ... Opportunities and Business Expansion Strategies for Suppliers ... During the next ten years, the ...
... YORK, March 7, 2011 NeoStem, Inc. (NYSE Amex: ... operations in the U.S. and China, is pleased to ... Vice President of Strategic Business Development. Jason was formerly ... the firm,s research effort in emerging biotechnology companies. Jason,s ...
Cached Biology Technology:Reportlinker Adds Biomarkers - Technologies, Markets and Companies 2Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers 2NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development 2NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development 3
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
Anti-human C5a/C5a des-Arg (neo-epitode), Clone 2952, Monoclonal Antibody...
...
Reacts with the 80 kDa fragment of the M-chain of human merosin....
Biology Products: